BOARD OF DIRECTORS

Abarceo Pharma is a spin-out of Lund University Diabetes Center founded in 2017 by Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi world-renowned scientists in diabetes research and beta-cell biology. Abarceo Pharma has identified a novel diabetes target VDAC1 located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their insulin again, naturally. The company founders were the first to describe that voltage-dependent anion channel 1 (VDAC1) is dysfunctional and presents a novel target in Type 2 Diabetes (T2D). VDAC1 is a key mitochondrial protein regulating the energy production in cells and has been implicated in multiple diseases with underlying mitochondrial dysfunction including neurodegenerative and cardiovascular disease (CVD). These diseases are closely related to T2D and are often referred to as comorbidities.

 Abarceo Pharma is developing a small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D.

Adam Bruce

Adam Bruce

Chairman of the Board

Adam Bruce comes with a background in product innovation and entrepreneurship. He’s been instrumental in establishing TikoMed, a company with now two projects in Phase 2 clinical development for neurology and cell therapy. During his time at TikoMed he has served in positions as CEO, Chairman, Business Development, and project VP. Over the years Adam has provided advice on financing and strategic development in various constellations for life science and med-tech companies. Adam holds a business degree from Lund University.

Annie Chandy

Annie Chandy

Vice- Chairman of the Board

Annie Chandy is part of the Lund University Technology Transfer Unit where her responsibility is to help academics evaluate and develop early diabetes and other life science research projects and mature them along a commercial path to increase their commercial value. She manages the project evaluation process, develops the projects along a commercial path, manages pharma industry relationships, and maintains a portfolio of IP projects. She represents LU Holding on the Board and with her understanding of the Swedish soft funding, the landscape has helped to fund the company through non-dilutive sources in its early days.

Ulrich Koch

Ulrich Koch

Independent Board Member

Ulrich S. Koch worked for 35+ years in the pharmaceutical industry at Schering and Bayer having been based in Germany, in the United Kingdom, and in the USA. During this time he was responsible for Strategic Marketing, Licensing, and Business Development, managed international teams, negotiated several important Licensing and M&A deals, and coordinated the respective implementation of such partnerships. Currently, Ulrich Koch works as Senior Transaction Manager for the New York-based investment firm Ferghana Partners and provides additional partnering services as head of Venice Pharma Consultancy. For 20+ years he is also a board member, speaker, and trainer within the European IPLS network (International Partnering in Life Science Society). Ulrich is an economist by training.

Helen Petersson

Helen Petersson

Board Member

Helen Petersson works as an Investment Manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process, which means finding, investing in and developing innovative companies with growth potential and implement an exit strategy from the holding through a listing or strategic sale. Currently, she is the Investment Manager of 6 of Almi Invest South’s portfolio companies and a board member of 5 companies.

She earned a PhD in Tumor Immunology and began her career as a translational cancer researcher. Before joining Almi Invest, Helen was a Senior Project Manager at the Danish-Swedish life science cluster organization Medicon Valley Alliance.

Milan Zdravkovic

Milan Zdravkovic

Board Member

Milan Zdravkovic is a seasoned pharma executive with experience from numerous senior R&D positions supporting approval of therapies within diabetes, growth hormone disorders, obesity, and immunology. He is currently Chief Medical Officer and Head of R&D at SNIPRBIOME, a Danish CRISPR microbiome biotech. Prior to this, he acted in the same role at Swedish Orphan Biovitrum AB, where he oversaw a significant expansion of the R&D portfolio within haematology and immunology. He spends his early pharma career working 18 years at Novo Nordisk as Corporate Vice President heading up R&D teams in therapeutic areas such as GLP-1 and insulin.

Milan Zdravkovic holds an MD and Ph.D. from the University of Aarhus, Denmark, and an MSc in Pharmaceutical Medicine from the University of Surrey, UK. In addition, he has received training in management and strategy from Harvard University and INSEAD.